Kwiminyaka yakutshanje, i-GLP-1 receptor agonists (GLP-1 RAs) iye yavela njengomdlali ophambili kunyango lwesifo sikashukela kunye nokukhuluphala, ibe yinxalenye ebalulekileyo yolawulo lwezifo ze-metabolic. La mayeza awadlali nje indima ebalulekileyo ekulawuleni iswekile yegazi kodwa abonisa nemiphumo ephawulekayo ekulawuleni ubunzima kunye nokukhuselwa kwentliziyo. Ngenkqubela phambili eqhubekayo kuphando, izibonelelo zempilo zamachiza e-GLP-1 ziya ziqondwa kwaye zixatyiswe.
I-GLP-1 yi-hormone ye-incretin eyenzekayo ngokwendalo ekhutshwa ngamathumbu emva kokutya. Ivuselela ukukhuselwa kwe-insulin, icinezela ukukhutshwa kweglucagon, kwaye icothise ukuphuma kwesisu, zonke ezinegalelo kulawulo olungcono lweswekile yegazi. I-GLP-1 i-receptor agonists, njenge-semaglutide, i-liraglutide, kunye ne-tirzepatide, ziphuhliswa ngokusekelwe kwezi ndlela kwaye zibonelela ngeendlela zonyango ezisebenzayo kwizigulane ezine-2 yeswekile.
Ngaphandle kolawulo lwe-glycemic, amayeza e-GLP-1 abonise amandla akhethekileyo ekunciphiseni ubunzima. Ngokusebenza kwinkqubo ye-nervous central, banciphisa ukutya kunye nokuphucula ukuhlutha, okukhokelela ekunciphiseni kwendalo kwikhalori yokutya. Izifundo zeklinikhi zibonise ukuba izigulana ezisebenzisa amayeza e-GLP-1 zifumana ukwehla okubonakalayo kobunzima nakwixesha elifutshane, kwaye ukusetyenziswa kwexesha elide kunokukhokelela ekunciphiseni ubunzima be-10% ukuya kwi-20%. Oku akuphuculi nje kuphela umgangatho wobomi kodwa kunciphisa umngcipheko weemeko ezinxulumene nokutyeba kakhulu ezifana noxinzelelo lwegazi, i-hyperlipidemia, kunye nesifo sesibindi esinamafutha angekho utywala.
Okubaluleke ngakumbi, amanye amachiza e-GLP-1 abonise izibonelelo ezithembisayo zentliziyo. Uphando lubonisa ukuba i-GLP-1 i-receptor agonists inokunciphisa umngcipheko weziganeko ezinkulu ze-cardiovascular, kubandakanywa ukuhlaselwa kwentliziyo kunye nokubetha, ukunika ukhuseleko olongezelelweyo kwizigulane ezinesifo se-cardiovascular disease okanye abo basengozini enkulu. Ngaphezu koko, izifundo zakwangoko zihlola usetyenziso lwazo olunokubakho kwiingxaki ze-neurological ezifana ne-Alzheimer's kunye nesifo sika-Parkinson, nangona ubungqina obuninzi bufunekayo kwezi ndawo.
Ewe kunjalo, amayeza e-GLP-1 anokuza neziphumo ebezingalindelekanga. Eyona nto ixhaphakileyo kukungakhululeki kwesisu esifana nesicaphucaphu, ukuhlanza, kunye norhudo, ngakumbi ekuqaleni konyango. Nangona kunjalo, ezi zimpawu zihlala ziphela ngokuhamba kwexesha. Xa esetyenziswa phantsi kwesikhokelo sonyango lobuchwephesha, amayeza e-GLP-1 abonwa njengekhuselekile kwaye anyamezeleke kakuhle.
Ukuqukumbela, i-GLP-1 receptor agonists iye yavela kunyango lwesifo seswekile esiqhelekileyo ukuya kwizixhobo ezinamandla zolawulo olubanzi lwe-metabolic. Abancedi kuphela abaguli ukulawula ngcono iswekile yegazi kodwa banika ithemba elitsha lokulawula ukutyeba kunye nokukhusela impilo yentliziyo. Njengoko uphando luqhubela phambili, amayeza e-GLP-1 kulindeleke ukuba adlale indima enkulu ngakumbi kwikamva lokhathalelo lwempilo.
Ixesha lokuposa: Jul-11-2025